US › Healthcare

Solid Biosciences LLC (SLDB)

US · Healthcare · Biotechnology

$8.62+7.48%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-56.7M

Profit YoY

-44.4%

EPS

$-0.52

EPS estimate

$-0.44

EPS came in at -0.52 against a street estimate of -0.44 — a miss of 17.9%.

Key statistics

Market cap

$793.5M

Forward P/E

0.0

P/B

2.12

Book value

$3.80

EPS (TTM)

$-1.92

52-week high

$11.45

52-week low

$3.79

50-day MA

$8.29

200-day MA

$6.80

Beta

2.36

Analyst view

Analysts rate Solid Biosciences LLC a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $17.50.

Shareholding

Insiders

0.74%

Institutions

104.74%

Largest institutional holders

Fund	Stake
Perceptive Advisors LLC	12.09%
Bain Capital Life Sciences Investors, LLC	9.96%
RA Capital Management, LLC	9.49%
Siren, L.L.C.	7.81%
Vestal Point Capital LP	5.08%
BlackRock Inc	5.04%
HHG PLC	4.07%
FMR Inc	3.66%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Solid Biosciences LLC — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.